U.S. markets closed

Rafael Holdings, Inc. (RFL)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
36.84+0.52 (+1.43%)
At close: 4:00PM EDT
Sign in to post a message.
  • F
    FelixH
    They continue to build a highly competent leadership time. For a long time I was hoping to sell upon publication of phase 3 data… now I’m thinking about keeping them long term. With a complete therapeutic approach of multiple drugs targeting cancer metabolism at various stages; I believe we are looking at a completely new treatment approach.
    Bullish
  • A
    Anthony
    back to 43 end of week
  • J
    James
    Charles Lorenzo was right !!!!
  • Y
    Yahoo Finance Insights
    🚨 Unusual Volume 🚨
    XERS - Vol 79335829 (+4279.49%), Price 2.5801, https://finance.yahoo.com/quote/XERS?source=unusualvolume
    CIO - Vol 2964525 (+1254.08%), Price 16.22, https://finance.yahoo.com/quote/CIO?source=unusualvolume
    HEXO - Vol 46976187 (+1192.64%), Price 2.3000, https://finance.yahoo.com/quote/HEXO?source=unusualvolume
    MATW - Vol 779649 (+1130.95%), Price 34.33, https://finance.yahoo.com/quote/MATW?source=unusualvolume
    RFL - Vol 720036 (+1072.70%), Price 38.55, https://finance.yahoo.com/quote/RFL?source=unusualvolume
  • A
    Anthony
    why is stock dropping?
  • r
    robert
    Look at the board and advisory council. I think there are a half dozen Nobel prize winners. No float, can go to $100 or $10 but what a ride
  • J
    James
    An oral form of devimistat (RFL-618) is in development, as are three second generation compounds (RFL-5800/5990/6520). INDs are expected to be filed either this and/or next year.

    In the first PhIII (metastatic pancreatic) the company is expecting a data readout by Q3. In the second PhIII (R/R AML), an IA will be conducted by Q2.
  • C
    Coco
    $RLFTF conversation
    in 15 min is the interview from Javitt on the NeuroRX Media Website.

    Dont forgot to watch what he is saying.

    #RFL-100 #HOLDSTRONG
  • a
    a
    to the Moon...
    to Infinity and beyond..!!!
  • F
    FelixH
    Got some new highs today following an exciting publication yesterday.
    http://ddn-news.com/news?newsarticle=13372 It’s a worthwhile read! If you are new to this holdings company, Rafael holdings owns a majority share in Rafael pharmaceuticals, as well as a sizable real estate portfolio. The below article does an excellent job explaining just how unique and likely influential their lead compound CPI-613 is to the future of cancer treatment.
    DDNews: News Article
    DDNews: News Article
    ddn-news.com
  • A
    Anthony
    Great stock!!!
  • F
    FelixH
    150 patient phase 3 AML trial completed; wohoo! Can’t wait for the data of both Armada 2000 and Avenger 500...let’s hope they become new standards of care. It could save so many lives.
    Bullish
  • a
    a
    up 8% today... here is reason...
    CRANBURY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc.(“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) in older patients with relapsed or refractory acute myeloid leukemia (AML) is now active and enrolling patients in South Korea. The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone (CHAM). The clinical trials will kick off with an investigator meeting held on Sept. 19 in Seoul.
    “Bringing our Phase 3 clinical trials for patients with AML to South Korea will mark the first of Rafael’s devimistat trials in Asia, with additional trials in the region planned for patients with pancreatic cancer in the near future,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “This expansion is part of our larger goal to treat patients with unmet clinical needs around the world.” 
    The study, currently in multiple U.S. and European sites, will now expand to the following four sites in South Korea: Asan Medical Center, Samsung Medical Center, Seoul National University Hospital and Severance Hospital. Lead investigators include Dr. Eun-Ji Choi, Dr. Jun Ho Jang, Dr. Sung-Soo Yoon and Dr. June-Won Cheong.
    “The opening of clinical trials in South Korea is imperative for treating elderly patients with refractory AML in the region, as they have a lower survival rate,” said Dr. Jorge Cortes, principal investigator on the global trial. “I have hopes for the success of devimistat in treating patients.”
  • a
    a
    ok... here is the scoop...

    GlobeNewswire



    CONTACT US

    REGISTERSIGN IN

    ENGLISHFRANÇAIS



    EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer

      

    January 10, 2019 08:00 ET | Source: Rafael Pharmaceutical Inc.

    Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency (EMA) has granted orphan drug designation to devimistat (CPI-613®), the Company’s lead Altered Metabolism Directed (AMD) platform drug candidate, for the treatment of Metastatic Pancreatic Cancer.
    Pancreatic cancer is a deadly disease, with a mortality rate of more than 95% within five years. Because pancreatic cancer does not present with recognizable symptoms in its early stages, most patients are diagnosed with advanced disease that affords limited treatment options. Chemotherapy is currently the only treatment option for metastatic pancreatic cancer. National Comprehensive Cancer Network (NCCN) treatment guidelines recommend FOLFIRINOX or gemcitabine plus nab-paclitaxel for first line treatments for patients who are healthy enough to tolerate them and who have a support system for these relatively aggressive medical therapies.
    Devimistat is a first-in-class drug developed based on Rafael’s Altered Metabolism Directed (AMD) platform. Devimistat targets the altered regulation of metabolic processes specific to cancer cells. It is highly specific, simultaneously attacking multiple targets, minimally toxic and has broad spectrum activity across a wide variety of cancers. Devimistat is currently being evaluated in 7 trials as a single agent, as well as in combination with standard drug therapies for hematological malignancies and solid tumors. To date, over 300 subjects have received one or more doses of devimistat with encouraging response rates and durations of response in several tumor types. 
  • C
    Charles_Lorenzo
    Just own and enjoy the ride #ToTheMoon
    Bullish
  • A
    Autopilot
    Something huuuuge is brewing... up big on no news is good news.
  • d
    dlord
    Our time is nigh. We will soon see RFL surge by end of Q3 as one of the highest gainers imo on the market with data that will raise eyebrows across the world!
  • a
    a
    a NEW high today..!!
  • C
    Charles_Lorenzo
    Hope is that successful trials will allow Rafael Pharmaceuticals will receive expedited FDA approval by late 2020.
    Hope is that successful trials will allow Rafael Pharmaceuticals will receive expedited FDA approval by late 2020.
    www.jpost.com
  • R
    Ray
    RFL Reports: Revenue of $1.1 million compared to $1.3 million
    Loss from operations of $731 thousand compared to $164 thousand
    Loss attributable to Rafael Holdings of $531 thousand compared to $65 thousand
    Loss per share of $0.04 compared to $0.01
    Stock price has gone from $3 to >$10 in 2 month with this financial, no product, no news; what a manipulation